4CPS-028 Real-life study of the use of cyclin-dependent kinase inhibitors in hormone receptor-positive breast cancer
Year: 2025
Type: conference-paper
Study design: Observational Study
Abstract: Background and Importance There are no head-to-head comparisons between these three molecules in certain aspects that are important to know in the day-to-day patient medication management. Aim and Objectives The main objectives are to analyse whether there are differences between each of the treatment groups (ribociclib, palbociclib, abemaciclib) in terms of treatment discontinuations, interruptions and dose reductions. In addition, to determine whether there are differences in the number of visits to the oncology department, emergency room or number of admissions. Secondary objectives are to find out whether patients with lower BMI (under 25) or older (over 60) require greater dose reductions and/or greater number of treatment interruptions. Material and Methods Descriptive, retrospective, multidisciplinary study (oncologist) using a pseudonymised database of 120 patients (40 in each group). Data were collected from the medical records. All statistical tests were applied with a confidence level of 95% and IBM SPSS version 26.0 was used. Results The mean time to first treatment discontinuation was 29.2 (± 16.4) days in the total group, with no statistically significant differences between the three groups (P= 0.389). There were statistically significant differences at 3 months in the number of emergency department visits and admissions in the abemaciclib group compared to the other two groups, with the abemaciclib group having the most hospital visits for either of these two reasons (P= 0.042 and P=0.013 respectively). Ribociclib was the drug with the highest number of treatment discontinuations due to adverse effects (20%) with no differences between groups (p=0.271). Furthermore, at 3 months of treatment only 20% of patients had required a dose reduction. At 6 months of treatment this percentage was 33.3%,similar to the percentages in clinical trials. There was no difference in the number of patients with reduced dose at 6 months (p=0.671). Patients with BMI less than 25 had more treatment interruptions during the first 3 months (p=0.014), not reflected in greater dose reductions. There were no statistically significant differences at 3 months (p=0.144) or 6 months (p=0.065) in dose reductions according to age. Conclusion and Relevance These are fairly safe drugs, responsible for few discontinuations or dose reductions due to adverse effects. Neither age nor BMI are parameters that are clearly associated with greater dose reductions. References and/or Acknowledgements Conflict of Interest No conflict of interest
Institution: Hospital General Universitario Gregorio Marañón
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4408376695